Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD)
Glob J Addict Rehabil Med
.
2017 Feb;1(2):555556.
doi: 10.19080/GJARM.2017.01.555556.
Epub 2017 Feb 23.
Authors
Kenneth Blum
1
2
3
4
5
6
7
8
9
10
,
Margaret A Madigan
4
,
Lyle Fried
7
,
Eric R Braverman
6
,
John Giordano
5
,
Rajendra D Badgaiyan
9
Affiliations
1
Department of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, USA.
2
Department of Psychiatry and Behavioral Sciences, Keck Medicine University of Southern California, USA.
3
Division of Applied Clinical Research & Education, Dominion Diagnostics, USA.
4
Department of Neurogenetics, Igene, USA.
5
National Institute for Holistic Addiction Studies, USA.
6
Department of Clinical Neurology, Path Foundation NY, USA.
7
Division of Neuroscience Based Addiction Therapy, The Shores Treatment & Recovery Center, USA.
8
Eötvös Loránd University, Institute of Psychology, Europe.
9
Department of Psychiatry, Wright State University Boonshoft School of Medicine and Dayton VA Medical Center, US.
10
Division of Reward Deficiency Syndrome, Nupathways, Inc., Innsbrook, MO, USA.
PMID:
29399668
PMCID:
PMC5796781
DOI:
10.19080/GJARM.2017.01.555556
No abstract available
Grants and funding
R01 NS073884/NS/NINDS NIH HHS/United States